BioCryst makes case for oral HAE therapy even as Phase III data disappoint investors

Despite reporting Phase III efficacy data for its oral hereditary angioedema therapy that fell short of marketed injectable therapies to prevent HAE attacks, BioCryst believes the demand for an oral option will enable BCX7353 to succeed as a front-line treatment. The company reiterated its plans to submit an NDA to FDA in

Read the full 520 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE